

Federica Casiraghi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5277937/publications.pdf>

Version: 2024-02-01

57
papers

3,290
citations

172207

29
h-index

143772

57
g-index

59
all docs

59
docs citations

59
times ranked

3910
citing authors

#	ARTICLE	IF	CITATIONS
1	Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells. <i>Journal of Immunology</i> , 2008, 181, 3933-3946.	0.4	405
2	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 412-422.	2.2	273
3	Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1007-1018.	3.0	224
4	B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1811-1822.	3.0	174
5	Recellularization of Well-Preserved Acellular Kidney Scaffold Using Embryonic Stem Cells. <i>Tissue Engineering - Part A</i> , 2014, 20, 1486-1498.	1.6	169
6	Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 2373-2383.	2.6	151
7	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. <i>Transplant International</i> , 2013, 26, 867-878.	0.8	148
8	Mesenchymal stromal cells in renal transplantation: opportunities and challenges. <i>Nature Reviews Nephrology</i> , 2016, 12, 241-253.	4.1	132
9	Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies. <i>Stem Cell Reviews and Reports</i> , 2013, 9, 65-79.	5.6	125
10	Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury. <i>Transplantation</i> , 2007, 84, 956-964.	0.5	94
11	Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. <i>Thrombosis and Haemostasis</i> , 2005, 93, 443-452.	1.8	81
12	Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: Implications for dialysis hypotension. <i>American Journal of Kidney Diseases</i> , 1998, 32, 115-124.	2.1	78
13	In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development. <i>Journal of Immunology</i> , 2013, 191, 2818-2828.	0.4	75
14	Mesenchymal stromal cells to promote solid organ transplantation tolerance. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 51-58.	0.8	70
15	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. <i>Transplantation</i> , 2009, 88, 614-619.	0.5	64
16	Thymic Dendritic Cells Express Inducible Nitric Oxide Synthase and Generate Nitric Oxide in Response to Self- and Alloantigens. <i>Journal of Immunology</i> , 2000, 164, 4649-4658.	0.4	63
17	Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1359.	2.2	58
18	Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 362-375.	3.0	55

#	ARTICLE	IF	CITATIONS
19	Mesenchymal Stromal Cells for Transplant Tolerance. <i>Frontiers in Immunology</i> , 2019, 10, 1287.	2.2	54
20	SEQUENTIAL MONITORING OF URINE-SOLUBLE INTERLEUKIN 2 RECEPTOR AND INTERLEUKIN 6 PREDICTS ACUTE REJECTION OF HUMAN RENAL ALLOGRAFTS BEFORE CLINICAL OR LABORATORY SIGNS OF RENAL DYSFUNCTION. <i>Transplantation</i> , 1997, 63, 1508-1514.	0.5	53
21	Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. <i>Kidney International</i> , 1999, 55, 984-994.	2.6	51
22	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. <i>Kidney International</i> , 2001, 60, 653-663.	2.6	49
23	Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. <i>Arthritis and Rheumatism</i> , 2007, 56, 1629-1637.	6.7	46
24	The Toll-IL-1R Member Tir8/SIGIRR Negatively Regulates Adaptive Immunity against Kidney Grafts. <i>Journal of Immunology</i> , 2009, 183, 4249-4260.	0.4	46
25	Mesenchymal stromal cells for tolerance induction in organ transplantation. <i>Human Immunology</i> , 2018, 79, 304-313.	1.2	40
26	Peripheral donor leukocytes prolong survival of rat renal allografts. <i>Kidney International</i> , 1999, 56, 1101-1112.	2.6	33
27	Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response. <i>American Journal of Transplantation</i> , 2017, 17, 2312-2325.	2.6	32
28	Mesenchymal stromal cells to promote kidney transplantation tolerance. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 47-53.	0.8	30
29	Pretransplant Donor Peripheral Blood Mononuclear Cells Infusion Induces Transplantation Tolerance by Generating Regulatory T Cells. <i>Transplantation</i> , 2005, 79, 1034-1039.	0.5	27
30	Renal Prostacyclin Biosynthesis Is Reduced in Children With Hemolytic-Uremic Syndrome in the Context of Systemic Platelet Activation. <i>American Journal of Kidney Diseases</i> , 1992, 20, 144-149.	2.1	26
31	Thymic Microchimerism Correlates with the Outcome of Tolerance-Inducing Protocols for Solid Organ Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2815-2826.	3.0	25
32	Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2010, 15, 731-737.	0.8	23
33	Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 79-85.	0.8	23
34	Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. <i>Stem Cells Translational Medicine</i> , 2020, 9, 427-432.	1.6	20
35	Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , 2021, 21, 2795-2809.	2.6	20
36	Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c+F4/80+ Macrophages through IL-1R8 Regulation. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 517-531.	3.0	16

#	ARTICLE	IF	CITATIONS
37	Pluripotent stem cells and tolerance induction in organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 86-93.	0.8	15
38	The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting. <i>Transplant International</i> , 2020, 33, 833-840.	0.8	15
39	Assessment of Anti-donor T Cell Proliferation and Cytotoxic T Lymphocyte-Mediated Lympholysis in Living Donor Kidney Transplant Patients. <i>Methods in Molecular Biology</i> , 2014, 1213, 355-364.	0.4	15
40	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. <i>Transplantation</i> , 2019, 103, 1121-1130.	0.5	14
41	Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 618243.	2.2	14
42	Peripheral donor leukocytes prolong survival of rat renal allografts. <i>Kidney International</i> , 1999, 56, 1101.	2.6	14
43	Mesenchymal stromal cells in kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 40-46.	1.0	13
44	Cellular therapies in organ transplantation. <i>Transplant International</i> , 2021, 34, 233-244.	0.8	11
45	Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 2349-2354.	0.4	10
46	Mini-€organs forum: how to advance organoid technology to organ transplant community. <i>Transplant International</i> , 2021, 34, 1588-1593.	0.8	10
47	Embryonic Stem Cells, Derived Either after In Vitro Fertilization or Nuclear Transfer, Prolong Survival of Semiallogeneic Heart Transplants. <i>Journal of Immunology</i> , 2011, 186, 4164-4174.	0.4	9
48	Mesenchymal Stromal Cells for AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 7-9.	3.0	7
49	Recent advances in immunosuppression and acquired immune tolerance in renal transplants. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F446-F453.	1.3	5
50	Update on mesenchymal stromal cell studies in organ transplant recipients. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 27-34.	0.8	4
51	Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. <i>Kidney International</i> , 2007, 71, 1132-1141.	2.6	3
52	Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice. <i>Stem Cell Research and Therapy</i> , 2021, 12, 332.	2.4	3
53	Vein Suturing Results in Worse Lung Graft Outcomes Compared to the Cuff Method. <i>European Surgical Research</i> , 2019, 60, 106-116.	0.6	2
54	Mesenchymal stromal cell-based therapy in kidney diseases and transplantation. <i>Italian Journal of Medicine</i> , 2019, 13, 3-14.	0.2	1

#	ARTICLE	IF	CITATIONS
55	Chronic lung allograft pathology lesions in two rat strain combinations. Journal of Thoracic Disease, 2021, 13, 2833-2843.	0.6	1
56	Tâ€•and Bâ€•cell therapy in solid organ transplantation: current evidence and future expectations. Transplant International, 2021, 34, 1594-1606.	0.8	1
57	Donor hematopoietic cells: central versus peripheral tolerance. Current Opinion in Organ Transplantation, 2004, 9, 284-288.	0.8	0